After a long development saga that stretched across multiple companies, Rayaldee (calcifediol) was approved by the FDA to treat secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) who have serum total 25-hydroxyvitamin D levels lower than 30 ng/mL – a first for the indication, which affects predialysis patients.